Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Viveve Medical, Inc. - Common Stock
(NQ:
VIVE
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 18, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Viveve Medical, Inc. - Common Stock
< Previous
1
2
Next >
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
January 17, 2023
Via
ACCESSWIRE
Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded
December 15, 2022
Via
ACCESSWIRE
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
December 01, 2022
Via
ACCESSWIRE
InvestorNewsBreaks — Viveve Medical Inc. (NASDAQ: VIVE) Releases Q3 2022 Financial Report, Corporate Update
November 11, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
Via
ACCESSWIRE
Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
October 04, 2022
Via
ACCESSWIRE
Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
Via
ACCESSWIRE
Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022
October 27, 2022
Via
ACCESSWIRE
Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout
September 27, 2022
Via
ACCESSWIRE
Viveve to Participate in Ladenburg Thalmann Healthcare Conference
September 22, 2022
Via
ACCESSWIRE
Viveve to Participate in Alliance Global Partners Virtual MedTech Conference
September 15, 2022
Via
ACCESSWIRE
Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022
Via
ACCESSWIRE
Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022
July 28, 2022
Via
ACCESSWIRE
Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022
July 28, 2022
ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today...
From
Viveve Medical, Inc.
Via
AccessWire
Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan
July 12, 2022
ENGLEWOOD, CO / ACCESSWIRE / July 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today...
From
Viveve Medical, Inc.
Via
AccessWire
Topics
Intellectual Property
Viveve to Participate in H.C. Wainwright Global Investment Conference
May 17, 2022
ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will...
From
Viveve Medical, Inc.
Via
AccessWire
Viveve CEO Scott Durbin Named Among Top 50 Healthcare Technology Leaders of 2022 by Healthcare Technology Report
May 17, 2022
Durbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 /...
From
Viveve Medical, Inc.
Via
AccessWire
Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022
Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET...
From
Viveve Medical, Inc.
Via
AccessWire
Viveve to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 12, 2022
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Viveve Medical, Inc.
Via
AccessWire
Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update
March 17, 2022
Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post...
From
Viveve Medical, Inc.
Via
AccessWire
Viveve to Report Full Year 2021 Financial Results and Provide Corporate Update on March 17, 2022
March 03, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021...
From
Viveve Medical, Inc.
Via
AccessWire
Healthcare Technology Report Names Viveve Regulatory Executive Among Top 25 Women Leaders in Medical Devices
January 13, 2022
Viveve SVP Suzon Lommel named to list for second consecutive year for efforts to advance innovative technologies to treat stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / January 13,...
From
Viveve Medical, Inc.
Via
AccessWire
Viveve to Participate in H.C. Wainwright BIOCONNECT Conference
January 04, 2022
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer,...
From
Viveve Medical, Inc.
Via
AccessWire
Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence
December 14, 2021
Major milestone achieved in Company's advance toward a new U.S. SUI indication ENGLEWOOD, CO / ACCESSWIRE / December 14, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused...
From
Viveve Medical, Inc.
Via
AccessWire
Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 11, 2021
- Total revenue of $1.6M reported for Q3 - Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4 ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve...
From
Viveve Medical, Inc.
Via
AccessWire
Topics
Intellectual Property
Viveve to Host Conference Call on November 11, 2021 to Report Third Quarter Financial Results and Provide Corporate Update
November 02, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third...
From
Viveve Medical, Inc.
Via
AccessWire
Viveve Announces Issuance of New Device and Methods Patent in U.S
October 28, 2021
Issuance further expands and strengthens Company's intellectual property portfolio ENGLEWOOD, CO / ACCESSWIRE / October 28, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company...
From
Viveve Medical, Inc.
Via
AccessWire
Topics
Intellectual Property
Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia
September 23, 2021
Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Viveve Medical, Inc....
From
Viveve Medical, Inc.
Via
AccessWire
Topics
Intellectual Property
Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive...
From
Viveve Medical, Inc.
Via
AccessWire
Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 12, 2021
Total revenue of $1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarter Pivotal SUI PURSUIT trial enrollment on-track for...
From
Viveve Medical, Inc.
Via
AccessWire
Topics
Intellectual Property
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.